SecBot SecBot

SRZN

Surrozen, Inc.
Nasdaq· Biological Products, (No Diagnostic Substances)· Inc. DE· CIK 0001824893 Biotech & Drug Discovery
$27.28 +1.80 (+7.06%)
Oct 26 4:00 PM ET · prev $25.48
Market cap
$453.5M
Small cap
Consensus
Buy
92% Buy or better · 12 analysts
Median target
$48.00
+76% · range $40.00–54.00
1 year
+98.7%
from $13.73 · Oct 28
30 days
−8.0%
from $29.64
52-week range
$11.80–34.13
−20% from high · low Nov 10
Avg volume 20D
639.1K
Sep 30 spike 1.66M
Short interest
3.13M
≈17.6% of shares · +43.0%
Days to cover
4.8
at average volume
Insider net
−$437.4K
1 buyer · 4 sellers · since Feb 3
New fund stakes
1
Q2 2026 13F · 0 exits
Filing reports
8
analyzed by SecBot
SecBot read BULLISH 8 reports · 90 days
Balance 0 bearish · 3 bullish · 1 mixed · 4 neutral oldest → newest, height = score
Avg score ·High conf. 6/8
Strongest BULLISH Surrozen closed the second and final tranche of its March 2025 private placement, raising ~$95.1M in gross…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersMIXED

    1 insider bought $3.3M at an average $24.54. 4 insiders sold $3.7M. Price is 11% above their cost.

  • InstitutionsBULLISH

    Q2 2026: 11 added (1 new), 5 trimmed or exited. Largest new: Point72 Asset Management, $17.2M.

  • AnalystsBULLISH

    11 of 12 rate it Buy or better. Every target is above the price.

  • EstimatesFLAT

    Current-quarter EPS estimate −$1.295 → −$1.320 over 90 days. 0 up, 2 down in 30 days.

  • Short sellersBUILDING

    Short interest +43.0% to 3.13M shares. 4.8 days to cover, ≈17.6% of shares.

  • TrendUPTREND

    14% above its 50-day average.

Who's buying

13F· Q2 2026
1
new positions
0
exits
$17.2M
in new stakes
FundMoveSharesValue
Point72 Asset Management, L.P.NEW664,272$17.2M
BlackRock, Inc.DOUBLED394,864$10.2M
VANGUARD CAPITAL MANAGEMENT LLCDOUBLED392,550$10.2M
GEODE CAPITAL MANAGEMENT, LLCDOUBLED201,652$5.2M
STATE STREET CORPDOUBLED133,084$3.5M
GOLDMAN SACHS GROUP INCDOUBLED113,531$2.9M
NORTHERN TRUST CORPDOUBLED63,609$1.7M
VANGUARD FIDUCIARY TRUST COADD59,575$1.5M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

12 analysts
Buy 92% rate it Buy or better
Strong Buy4Buy7Hold1Sell0Strong Sell0
12-month targets · 4 analysts

Price is below the lowest target. Median implies +76%.Targets as of Oct 28, 2026.

Recent actions
DateFirmActionRating
Sep 25, 2026HC Wainwright & Co.
MAINTAIN
MAINTAINBuy
Aug 20, 2026William Blair
INITIATE
INITIATEOutperform
Aug 10, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy
May 7, 2026HC Wainwright & Co.
MAINTAIN
MAINTAINBuy

Insider ledger

Form 4
$3.3M
bought · 1 insider
$3.7M
sold · 4 insiders
+11.2%
vs their $24.54 cost
DateInsiderTypeValue
Oct 20, 2026
COLUMN GROUP III GP, LP
10%+ Owner
EXERCISE$6.4M
Oct 20, 2026
Kutzkey Tim
Director
EXERCISE775,861 sh
Oct 20, 2026
COLUMN GROUP III GP, LP
10%+ Owner
EXERCISE258,620 sh
Oct 20, 2026
Kutzkey Tim
Director
EXERCISE$6.4M
Oct 20, 2026
Kutzkey Tim
Director
EXERCISE822,980 sh
Oct 20, 2026
Kutzkey Tim
Director
EXERCISE274,327 sh
Oct 20, 2026
Kutzkey Tim
Director
EXERCISE$6.0M
Oct 20, 2026
COLUMN GROUP III GP, LP
10%+ Owner
EXERCISE728,745 sh

Earnings setup

Estimates
−$1.32
EPS estimate, this quarter
−2%
estimate change, 90 days
0↑ 2↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$1.32-$1.33–-$1.30+0.0%$380.0K
Next Q-$0.98-$1.31–-$0.80+0.0%$380.0K
Current FY-$9.14-$9.14–-$9.14+0.0%$10.7M
Next FY-$4.19-$5.01–-$3.41+0.0%$1.5M

Short side

FINRA· Oct 15, 2026
3,131,276
shares short
+43.0%
vs prior settlement
4.8
days to cover
≈17.6%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 22, 2026 SEC
The Column Group entities filed Amendment No. 7 to their Schedule 13D on Surrozen, Inc., reporting a reduction in…
SC 13D/A — Impact 4/10
Oct 20, 2026 SEC
Surrozen closed the second and final tranche of its March 2025 private placement, raising ~$95.1M in gross proceeds…
8-K — Impact 6/10
Oct 20, 2026 Press
Surrozen closed the second tranche of its March 2025 private placement, raising ~$95.1M in gross proceeds after FDA…
Impact 6/10
Oct 20, 2026 Offering
Surrozen Announces Closing of Second Tranche of March 2025 Private Placement for $95.1 Million
Surrozen Announces Closing of Second Tranche of March 2025 Private Placement for $95.1 Million...
Oct 20, 2026 Insider
COLUMN GROUP III GP, LP acquired via exercise 548,653 shares
10%+ Owner @ $11.60 ($6.4M)
Oct 20, 2026 Insider
Kutzkey Tim acquired via exercise 775,861 shares
Director
Oct 20, 2026 Insider
COLUMN GROUP III GP, LP acquired via exercise 258,620 shares
10%+ Owner
Oct 7, 2026 SEC
Boxer Capital Management, LLC filed an amended Schedule 13G disclosing a 11.6% passive stake in Surrozen, Inc. as of…
SC 13G/A — Impact 4/10
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Oct 20, 2026
Offering
Surrozen Announces Closing of Second Tranche of March 2025 Private Placement for $95.1 Million
Surrozen Announces Closing of Second Tranche of March 2025 Private Placement for $95.1 Million...
Oct 15, 2026
Short interest
Short Interest: SRZN up 43% to 3.1M shares
Settlement 2026-10-15 | Days to cover: 4.77 | ≈17.59% of shares outstanding (est.)
Oct 2, 2026
FDA
Surrozen Announces FDA Clearance of IND Application for SZN-8141 for the Treatment of Diabetic Macular Edema
Surrozen Announces FDA Clearance of IND Application for SZN-8141 for the Treatment of Diabetic Macular Edema
Sep 15, 2026
Short interest
Short Interest: SRZN up 52% to 2.2M shares
Settlement 2026-09-15 | Days to cover: 12.68 | ≈18.68% of shares outstanding (est.)
Sep 2, 2026
Press release
Surrozen to Present at Upcoming Healthcare Investor Conferences
Surrozen to Present at Upcoming Healthcare Investor Conferences

SecBot reports

8 filings · 3 press releases · 2 bullish · 1 bearish · 5 neutral
All SRZN filing & press-release reports (11)